Here are five key notes:
1. Integra LifeSciences will pay an undisclosed cash amount to acquire the three products.
2. When the acquisition is complete, Integra will have rights to the Salto Talaris, Salto XT, Salto Mobile and Futura silastic toe replacement products outside the United States.
3. The transaction is subject to US Federal Trade Commission approval and the closure of the pending merger between Tornier and Wright Medical Group. The Tornier-Wright Medical Group merger is expected to receive clearance in the third quarter of 2015.
4. The revenues in the United States from the acquired products were around $15.5 million in 2015. This year, Integra expects the acquisition’s contribution to adjusted earnings per share to be immaterial given the timing of the transaction’s close, sales transition and expected costs associated with the integration.
5. The acquisition broadens Integra’s extremities product portfolio and allows the company to diversify the lower extremity portfolio as well as accelerate entry into the U.S. total ankle replacement segment.
More articles on orthopedic devices:
Bluegrass Orthopaedics & Hand Care implements the Navio system: 5 things to know
Medtronic dominates European VCF market—8 trends to watch
Titan Spine signs distribution agreement for Europe
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
